Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides
Autor: | Aditya Lele, Maureen T. Kelly, Christie M. Ballantyne, Carolyn M. Setze, Kamlesh M. Thakker, James C. Stolzenbach, Peter B. Jones |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2011 |
Předmět: |
Male
Simvastatin genetic structures Atorvastatin Pharmacology Gastroenterology chemistry.chemical_compound Fenofibrate Pharmacology (medical) Drug Interactions Rosuvastatin Calcium Hypertriglyceridemia Sulfonamides Anticholesteremic Agents General Medicine Middle Aged lipids (amino acids peptides and proteins) Drug Therapy Combination Female Cardiology and Cardiovascular Medicine medicine.drug medicine.medical_specialty Statin medicine.drug_class Article Fenofibric acid Pharmacotherapy Double-Blind Method Internal medicine medicine Humans Pyrroles Triglycerides Apolipoproteins B Cholesterol business.industry nutritional and metabolic diseases Cholesterol LDL medicine.disease Fluorobenzenes Pyrimidines chemistry Dyslipidemia Heptanoic Acids Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
Zdroj: | Cardiovascular Drugs and Therapy |
ISSN: | 1573-7241 0920-3206 |
Popis: | Objective The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia. Methods This is a post hoc analysis of a subset of patients (N = 92) with mixed dyslipidemia treated with moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 12 weeks in three controlled trials who had achieved LDL-C 200 mg/dL, and had fenofibric acid 135 mg added to the moderate-dose statin in a 52-week open-label extension study. Lipid and apolipoprotein (Apo) values and the proportion of patients meeting individual and combined treatment targets with combination therapy were determined at scheduled visits during the 52-week study and compared with baseline (start of extension study). Results Addition of fenofibric acid to moderate-dose statin for 52 weeks resulted in significant (P 200 mg/dL led to additional improvements in non–HDL-C, ApoB, HDL-C, and triglycerides that resulted in greater proportions of patients attaining optimal levels of the individual parameters as well as simultaneously achieving optimal levels of these parameters and LDL-C. |
Databáze: | OpenAIRE |
Externí odkaz: |